Dogwood Therapeutics Launches Phase 2b Clinical Trial for Non-Opioid Pain Treatment
![](https://www.stockwaveinsights.com/wp-content/uploads/2025/01/large_composition_female_doctor_holding_interactive_screen_with_medical_data_processing_dna_608b5420-780x470.jpeg)
$DWTX
Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a leading biopharmaceutical company, has announced the launch of its Phase 2b clinical trial, HALT-CINP, in early 2025. This trial is pivotal for evaluating Halneuron®, an innovative treatment for Chemotherapy-Induced Neuropathy (CINP), a type of neuropathic pain caused by chemotherapy.
Halneuron® has already shown promising results in earlier studies, with a significant reduction in cancer-related pain without the addiction risks associated with opioids. This makes it a potential breakthrough in the management of chemotherapy-related pain, a major issue for cancer patients undergoing treatment. Nearly one in three chemotherapy patients develop chronic neuropathy, making the need for effective treatments more urgent.
Greg Duncan, CEO of Dogwood Therapeutics, noted the potential market for Halneuron® could be as high as $1.5 billion, thanks to its ability to address the unmet need for non-opioid pain relief. The company has a successful track record in pain management, having developed and commercialized treatments like Celebrex, Lyrica, and Savella. Dogwood’s expertise in bringing effective therapies to market positions it well to make a lasting impact in pain management.
In addition to Halneuron®, Dogwood Therapeutics is advancing its antiviral pipeline, including treatments for conditions linked to dormant herpesviruses, such as fibromyalgia and Long-COVID. The company’s lead antiviral candidate, IMC-1, is expected to enter Phase 3 trials as a treatment for fibromyalgia, while IMC-2 is moving into Phase 2b studies for Long-COVID. This dual focus on pain management and antiviral therapies highlights Dogwood’s commitment to addressing critical medical needs.
With Halneuron® poised to revolutionize non-opioid pain treatments and ongoing antiviral developments, Dogwood Therapeutics is on track to address significant global health challenges. The company’s strategic focus on innovative solutions for chronic pain and viral illnesses positions it as a leader in advancing patient care. As clinical trials progress, Dogwood is set to make a meaningful impact on the lives of millions of patients worldwide.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**